Avenue Therapeutics, Inc. (ATXI) quarterly income statement — complete revenue, gross profit & net income history
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | -1.4M | 0 | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 714K | 954K | 724K | 1.11M | 1.91M | 1.6M | 3.16M | 2.82M | 3.71M | 2.12M | 2.07M | 3.92M | 6.43M | 3.91M | 663K | 605K | 2.86M | 914K | 872K | 951K |
| OpEx % of Revenue | - | - | - | 78.85% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 514K | 697K | 547K | 915K | 1.49M | 1.03M | 829K | 1.46M | 1.32M | 1.14M | 1.16M | 896K | 984K | 3.37M | 469K | 454K | 1.05M | 524K | 594K | 623K |
| SG&A % of Revenue | - | - | - | 65.17% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 200K | 257K | 177K | 192K | 411K | 565K | 2.33M | 1.36M | 2.39M | 982K | 907K | 3.03M | 5.45M | 545K | 194K | 151K | 1.81M | 390K | 278K | 328K |
| R&D % of Revenue | - | - | - | 13.68% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -714K | -955K | -724K | 297K | -1.91M | -1.6M | -3.16M | -2.82M | -3.71M | -2.12M | -2.07M | -3.92M | -6.43M | -3.91M | -663K | -605K | -2.86M | -914K | -872K | -951K |
| Operating Margin % | - | - | - | 21.15% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 62.52% | 40.16% | 77.06% | 110.52% | 48.61% | 24.68% | -52.61% | 28.04% | 42.34% | 45.83% | -211.92% | -548.43% | -124.55% | -328.01% | 23.97% | 36.38% | -186.01% | 8.51% | 15.91% | 50.03% |
| EBITDA | -714K | -955K | -683K | 297K | -1.91M | -1.56M | -3.09M | -2.7M | 0 | 0 | 513K | -4.02M | -7.27M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA Margin % | - | - | - | 21.15% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 62.52% | 38.74% | 77.88% | 111% | - | - | -701.75% | 32.74% | 100% | - | - | - | - | - | - | - | 100% | - | 100% | 100% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 69K | 122K | 3.71M | 2.12M | 0 | 0 | 0 | 3.91M | 663K | 605K | 2.86M | 914K | 872K | 951K |
| EBIT | -714K | -955K | -683K | 297K | -1.91M | -1.56M | -3.09M | -2.7M | -3.71M | 617K | 513K | -4.02M | -7.27M | 1.69M | -662K | -604K | -2.86M | -914K | -872K | -951K |
| Net Interest Income | 18K | 24K | 34K | 31K | 32K | 24K | 51K | 52K | 49K | 22K | 9K | 57K | -295K | -1.14M | 1K | 1K | 2K | 1K | 1K | 2K |
| Interest Income | 18K | 24K | 34K | 31K | 32K | 24K | 51K | 52K | 49K | 22K | 9K | 57K | 37K | 16K | 1K | 1K | 2K | 1K | 1K | 2K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 332K | 1.16M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 19K | 219K | 41K | 32K | 47K | 37K | 69K | 122K | -642K | 2.74M | 2.58M | -93K | -1.17M | 4.44M | 1K | 1K | 2K | 1K | 1K | 2K |
| Pretax Income | -695K | -735K | -683K | 329K | -1.86M | -1.56M | -3.09M | -2.7M | -4.35M | 617K | 513K | -4.02M | -7.6M | 524K | -662K | -604K | -2.86M | -913K | -871K | -949K |
| Pretax Margin % | - | - | - | 23.43% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -695K | -709K | -683K | 335K | -1.85M | -1.54M | -3.08M | -7.19M | -4.34M | 640K | 526K | -4.01M | -7.54M | 575K | -662K | -604K | -2.86M | -913K | -871K | -949K |
| Net Margin % | - | - | - | 23.86% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 62.47% | 54.08% | 77.8% | 104.66% | 57.33% | -341.25% | -684.79% | -79.34% | 42.41% | 11.3% | 179.46% | -563.41% | -163.4% | 162.98% | 24% | 36.35% | -186.67% | 8.06% | 15.27% | 49.74% |
| Net Income (Continuing) | -695K | -726K | -683K | 329K | -1.86M | -1.56M | -3.09M | -2.7M | -4.35M | 617K | 513K | -4.02M | -7.6M | 524K | -662K | -604K | -2.86M | -913K | -871K | -949K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | -1.25M | -1.23M | -1.18M | -941K | -958K | -937K | -938K | -928K | -872K | -810K | -705K | -639K | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.21 | -0.22 | -0.21 | 0.11 | -0.62 | 4.54 | -1.92 | -6.43 | -7.72 | 0.03 | 4.86 | -38.74 | -101.57 | 3.57 | -0.45 | -0.41 | -153.75 | -0.75 | -0.79 | -0.86 |
| EPS Growth % | 66.13% | -104.85% | 89.06% | 101.71% | 91.97% | 18060% | -139.51% | 83.4% | 92.4% | -99.3% | 1180% | -9348.78% | 33.94% | 576% | 43.04% | 52.33% | -16983.33% | 16.67% | 15.05% | 50% |
| EPS (Basic) | -0.21 | -0.22 | -0.21 | 0.11 | -0.62 | 4.54 | -1.92 | -6.43 | -7.72 | 0.03 | 4.86 | -38.74 | -101.57 | 3.57 | -0.45 | -0.41 | -153.75 | -0.75 | -0.79 | -0.86 |
| Diluted Shares Outstanding | 3.29M | 3.13M | 3.18M | 3.18M | 2.97M | 1.6M | 1.6M | 1.12M | 562.04K | 25.6M | 8.11M | 103.44K | 5.57M | 1.41M | 1.47M | 1.46M | 1.4M | 1.22M | 1.11M | 1.1M |
| Basic Shares Outstanding | 3.29M | 3.13M | 3.18M | 3.18M | 2.97M | 1.6M | 1.6M | 1.12M | 562.04K | 25.6M | 8.11M | 7.76M | 5.57M | 1.41M | 1.47M | 1.46M | 1.4M | 1.22M | 1.11M | 1.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |